To The Moon

The gains that we've seen in the Mesoblast share price in recent weeks all stem from the blockbuster news that Mesoblast shared just before Christmas. As we covered back on 19 December, Mesoblast finally received the green light from the US Food and Drug Administration for its Ryoncil product. Ryoncil is a treatment for the deadly steroid-refractory acute graft versus host disease . It is the only therapy that has gained approval for use in children two months and older in the United States. Mesoblast has been preparing for this FDA decision throughout 2024. Optimism that the company would gain approval arguably fuelled much of the gains in the Mesoblast share price in the first half of the year. But the official green light really lit a rocket under the Mesoblast share price. On the day that this news became public, Mesoblast shares soared a whopping 54%. The company has continued to trend upwards ever since. So the Mesoblast share price is entering 2025 at a notable high. Let's se

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

Alibaba Group Holding Ltd said it would work to maintain its New York and Hong Kong stock exchange l

US equity futures fell on Monday as slowing economic growth and sticky inflation continued to handic

US Independence Day are around the corner. The U.S. market will be closed on Monday, 4 July 2022. Pl

KEY POINTSHang Seng Index was trading 1.30% higher after paring early gainsHK blue-chip stocks could